在尼泊尔帕坦医院,对伊马替尼治疗失败的费城染色体/BCR-ABL1阳性慢性髓性白血病患者使用伊马替尼耐药突变分析指导治疗
该研究回顾了2003年2月至2016年6月在尼泊尔注册的388例接受伊马替尼治疗的慢性髓性白血病(CML)患者,其中45例(女11例、男34例)因伊马替尼失败或耐药而接受BCR-ABL1突变分析,在33例中检出18种不同突变,T315I最常见,其次为F359V和M244V;存活者中16例接受尼洛替尼、5例达沙替尼、3例帕纳替尼。
要点
- 45例伊马替尼失败/耐药的CML患者中,33例检出18种不同的BCR-ABL1突变。
- T315I为最常见突变,其次为F359V和M244V,16种突变对伊马替尼显示中等活性至完全耐药。
- 存活患者中16例用尼洛替尼、5例达沙替尼、3例帕纳替尼,3例转诊印度,其中1例接受异基因骨髓移植。
核心结论
- 了解BCR-ABL1进一步获得性突变谱可能有助于选择更特异的靶向酪氨酸激酶抑制剂,这些药物可由GIPAP提供。
研究设计与样本
- 回顾性分析2003年2月至2016年6月在尼泊尔注册的388例接受伊马替尼治疗的CML患者(女149例、男239例)中45例(女11例、男34例)的BCR-ABL1突变情况。
主要发现
- 在33例患者中检出18种不同的BCR-ABL1突变;P-loop突变、激酶结构域突变和A-loop突变分别见于9例、16例和4例,其他突变见于5例。
- T315I突变最常见,其次为F359V和M244V;16种突变对伊马替尼显示中等活性至完全耐药。
- 45例评估BCR-ABL1突变的患者中,4例失访、14例死亡、27例仍存活。
- 存活患者中16例接受尼洛替尼、5例达沙替尼、3例帕纳替尼,3例转诊至印度,其中1例接受异基因骨髓移植。
临床怎么用
- 作者认为,了解BCR-ABL1进一步获得性突变谱可能有助于选择更特异的靶向酪氨酸激酶抑制剂,这些药物可由GIPAP提供。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance in a cohort of 388 imatinib-treated CML patients (149 Female and 239 male) registered between February 2003 and June 2016 in Nepal. Forty-five patients (11 female 34 male) were studied; 18 different BCR-ABL1 mutations were seen in 33 patients. P-loop mutation, Kinase domain and A-loop mutations were seen in 9, 16 and 4 patients respectively. Other mutations were seen in five patients. A T315I mutation was the most common mutation, followed by F359V and M244V. Sixteen mutations showed intermediate activity to complete resistance to Glivec. Among the 45 patients evaluated for BCR-ABL1 mutations, 4 were lost to follow-up, 14 died and 27 are still alive. Among the surviving patients, 16 are receiving Nilotinib, 5 Dasatinib and 3 Ponatinib, while 3 patients were referred to India, one of who received allogenic bone marrow transplantation. Understanding the spectrum of further acquired mutations in BCR-ABL1 may help to choose more specific targeted tyrosine kinase inhibitors that can be provided by GIPAP.
引用
- Kayastha GK, Ranjitkar N, Gurung R, et al. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. Br J Haematol. 2017. PMID: 28467002. doi:10.1111/bjh.14683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。